Unlock instant, AI-driven research and patent intelligence for your innovation.

Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof

A technology of heteroaryl and aryl, applied in chemical instruments and methods, compounds containing elements of Group 3/13 of the periodic table, pharmaceutical formulations, etc. Problems with different structures, weak ability to retain marks, etc.

Inactive Publication Date: 2007-05-30
MOLECULAR INSIGHT PHARMA
View PDF22 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Although different chelators are currently used in technetium binding, all of these tracers have one or more disadvantages that make them less than ideal: HYNIC requires a coligand; MAG3 can only interact with Tc(V) -Oxygen species; EDTA / DTPA is mainly used with Tc(V)-Oxygen and it retains label only poorly
Unfortunately, the structures of common fluorescent probes and radionuclide prosthetic groups differ significantly, which introduces a potential source of error when comparing in vitro and in vivo data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
  • Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
  • Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0060] 4. Preparation and characterization of Tc and Re fluorescent SAAC

[0061] Recently we reported the synthesis of a single amino acid chelate (SAAC) Tc(I) binding ligand (1, Figure 4). As shown in this article, SAAC can be combined with {M(CO) 3 } +1 The core forms an inert complex (M=Re, 99m Tc) and can be introduced into the polypeptide if it is a neutral amino acid. In order to prepare its Re complex to be fluorescent while maintaining the binding 99m Tc-capable SAAC-type ligand, in Na(OAc) 3 In the presence of BH, N-α-9-fluorenylmethoxycarbonyl-L-lysine is reacted with isoquinolinal to obtain bifunctional ligand 3 (Figure 4). The desired product can be prepared in the order of grams, and the desired product can be separated with excellent yield after column chromatography. By making ligand 3 and [NEt 4 ] 2 [Re(CO) 3 Br 3 ] Reaction to synthesize Re complex 4a. The TEA salt form of the complex is separated by column chromatography.

[0062] Figure 5a shows the absorption ...

Embodiment 1

[0427] 1. Synthesis of N-α-(tert-butoxycarbonyl)-N-ω-bis(2-pyridylmethyl)-L-lysine (L1c-Boc)

[0428] 2-Chloromethylpyridine hydrochloride (1.4g, 8.53mmol) and N-α-(tert-butoxycarbonyl)-L-lysine (1g, 4.06mmol) were dissolved in water and stirred at room temperature Five days, add 5mol dm at intervals-3 Aqueous NaOH keeps the pH at 8-10. The dark red solution was extracted with ethyl acetate, followed by 1mol dm -3 HCl acidified the aqueous phase to a pH of 3-4, extracted with chloroform and concentrated. The residue was purified by column chromatography using 10% chloroform in methanol to obtain N-α-(tert-butoxycarbonyl)-N-ω-bis(2-pyridylmethyl)-L-lysine (950mg, 55 %). 1 HNMR(CDCl 3 ), 300 MHz): 1.41 (s, 9H), 1.26-1.62 (m, 6H), 2.58 (t, 2H), 3.84 (s, 4H), 4.24 (t, H), 7.15 (m, 2H), 7.48 (d, 2H), 7.65 (m, 2H), 8.53 (d, 2H). 13 C NMR(CD 3 OD, 300MHz): 24.31 (C, CH 2 ), 26.66 (C, CH 2 ), 28.93 (3C, t-Bu), 33.15 (C, CH 2 ), 55.50(C, NCH 2 ), 60.12(2C, PyCH 2 ), 80.06 (C, NCH) 124.34 (...

Embodiment 2

[0430] 1. Synthesis of N-α-(2-pyridylmethyl)-N-ω-(tert-butoxycarbonyl)-L-lysine (L2d-Boc)

[0431] 2-Chloromethylpyridine hydrochloride (730mg, 4.46mmol) and N-α-(tert-butoxycarbonyl)-L-lysine (1g, 4.06mmol) were dissolved in water and stirred at room temperature for two Add 5mol dm every day -3 Aqueous NaOH keeps the pH at 8-10. The dark red solution was extracted with ethyl acetate, followed by 1mol dm -3 HCl acidified the aqueous phase to pH 6, then treated with chloroform, the desired product precipitated out, the precipitate was filtered and dried under vacuum (670 mg, 49%).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.

Description

[0001] Related application [0002] This application was filed on March 11, 2003, and is a partial continuation of U.S. Application Serial No. 10 / 386,403; it claims the priority of U.S. Provisional Patent Application Serial No. 60 / 363,142 filed on March 11, 2002. This application also claims priority to the U.S. Provisional Patent Application Serial No. 60 / 543,986 filed on February 12, 2004; and the U.S. Provisional Patent Application Serial No. 60 / 566,635 filed on April 29, 2004. The entire content is hereby incorporated as a reference. Background of the invention [0003] Due to the physical properties of their constituent radionuclides, radiopharmaceuticals can be used as diagnostic or therapeutic agents. Therefore, their application is not based on any pharmacological effects of their own. Most of these drugs in clinical use are diagnostic agents combined with gamma-emitting nuclides. Due to the physical, metabolic or biochemical properties o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/00C07F5/00C07D233/56
Inventor J·巴比奇W·C·埃克尔曼K·P·马雷斯卡J·W·瓦利安特J·朱比塔
Owner MOLECULAR INSIGHT PHARMA